Beta Drugs Ltd
Beta Drugs Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Company aims to grow at a rate between 23%-30% annually across key segments. - Domestic own branded business expected to continue 25%+ growth. - CDMO business expected to grow 5%-10% annually. - Exports are targeted to triple sales in next 2-3 years, with increased margins as regulated market approvals come through. - Dermatology (Derma) segment expected to grow from Rs. Beta Drugs projects a consolidated revenue growth rate of approximately 23% to 30% annually, targeting around 25% growth next year. - The Company aims to multiply and double branded sales in the next 3 years, with export sales expected to triple over 2-3 years. - EBITDA margins are expected to be stable around 23% to 25% consolidated. - The Dermatology segment, currently running at a loss, is expected to break even by FY '26 and grow to Rs.
From Beta Drugs Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Company aims to grow at a rate between 23%-30% annually across key segments.
- Domestic own branded business expected to continue 25%+ growth.
- CDMO business expected to grow 5%-10% annually.
- Exports are targeted to triple sales in next 2-3 years, with increased margins as regulated market approvals come through.
- Dermatology (Derma) segment expected to grow from Rs. 12.3 crores to Rs. 30 crores next year and Rs. 45-50 crores in 3 years.
- Consolidated revenue guidance for FY26 is around Rs. 450 crores, with a vision to reach Rs. 750 crores by FY28.
- New product launches (e.g., NDDS, Oral Therapy) and expansions in regulated markets expected to fuel growth.
2 more points from Beta Drugs Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Beta Drugs Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Major current capex includes building a new corporate office that will house regulatory, R&D, and other teams in one place.
- Investment of approximately Rs. 11 crores has been made in facility upgrades, mainly in Adley Formulations and Adley Lab.
- The Company is actively looking for land or a plant for backward integration to manufacture intermediates, reducing dependency on China and ensuring a reliable supply chain for KSMs.
- R&D team has around 10 people currently, with ongoing investment in scientific and drug delivery system innovations.
2 more points from Beta Drugs Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Beta Drugs Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The document does not explicitly mention the current or expected order book or pending orders in numeric terms.
- Rahul Batra mentions robust business operations with multiple strategic growth plans, indicating strong future demand.
- CDMO segment has about 30 clients, with 3 new clients added this year, suggesting ongoing and future order inflows.
- The company is actively preparing dossiers for regulatory approvals in multiple export markets (Mexico, Brazil, Thailand, Philippines, Vietnam), indicative of pending orders and potential new market entries.
2 more points from Beta Drugs Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Beta Drugs Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹94 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Beta Drugs Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharma. (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Arthneeti Pro · Annual
Beta Drugs Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Beta Drugs Ltd Q4 FY25 results?
Company aims to grow at a rate between 23%-30% annually across key segments. - Domestic own branded business expected to continue 25%+ growth. - CDMO business expected to grow 5%-10% annually. - Exports are targeted to triple sales in next 2-3 years, with increased margins as regulated market approvals come through. - Dermatology (Derma) segment expected to grow from Rs. Beta Drugs projects a consolidated revenue growth rate of approximately 23% to 30% annually, targeting around 25% growth next year. - The Company aims to multiply and double branded sales in the next 3 years, with export sales expected to triple over 2-3 years. - EBITDA margins are expected to be stable around 23% to 25% consolidated. - The Dermatology segment, currently running at a loss, is expected to break even by FY '26 and grow to Rs.
What is Beta Drugs Ltd share price analysis?
Beta Drugs Ltd currently shows a neutral. The stock trades at a P/E of 62.0 with a market cap of ₹2,828 Cr. Investors should review the full earnings analysis for detailed insights.
Is Beta Drugs Ltd planning capital expenditure?
Major current capex includes building a new corporate office that will house regulatory, R&D, and other teams in one place.
Keep Beta Drugs Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.